New blood test could see personalised prostate cancer treatment

The Institute of Cancer Research says blood tests for cancer promise to be truly revolutionary, as they are cheap and simple to use. Photograph: Elaine Thompson/AP

A new three-in-one blood test could pave the way to precision-personalised treatment for advanced prostate cancer, say scientists.

The test has the potential to transform the way the disease is tackled by targeting specific gene mutations, it is claimed.

By looking for cancer DNA in blood samples, researchers were able to identify men with defective BRCA genes who were likely to benefit from a class of drugs called Parp inhibitors.

They also used the test to monitor DNA in the blood after treatment started, so patients who were not responding could quickly be switched to an alternative therapy.

Finally, the same test was used to pick up signs of evolving cancer showing the first signs of drug resistance.

Prof Johann de Bono, who led the team at the Institute of Cancer Research in London, said: “We were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.

“We think it could be used to make clinical decisions about whether a Parp inhibitor is working within as little as four to eight weeks of starting therapy.

“Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.”

In future, the test could allow the Parp inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting those most likely to benefit, picking up early signs that the drug might not be working, and monitoring for emerging resistance.

Parp inhibitors such as olaparib block an enzyme used by cancer cells with defective BRCA 1 and 2 genes to repair their DNA.

When Parp is disabled, the cells die. The drugs do not generally work on cancer cells with functioning BRCA genes, because these are primary DNA repair tools that make Parp unnecessary. While some patients respond to the drugs for years, others either fail to respond at an early stage or develop resistant cancer.

The new test, described in the journal Cancer Discovery, was developed with the help of 49 patients enrolled in TOPARP-A, a Phase II clinical trial investigating the effectiveness of olaparib.

Men responding to the drug were found to experience an average drop in circulating cancer DNA of 49.6% after eight weeks of treatment. In contrast, cancer DNA levels rose by 2.1% in patients who did not respond.

Patients whose cancer DNA blood levels were lowered by olaparib survived an average of 17 months compared with 10.1 months for those whose levels remained high.

The scientists also conducted a detailed investigation of the genetic changes in cancer DNA among men who stopped responding to olaparib. They found that the cells acquired genetic changes that cancelled out the DNA repair defects making them susceptible to the drug.

Prof Paul Workman, chief executive of the Institute of Cancer Research, said: “Blood tests for cancer promise to be truly revolutionary. They are cheap and simple to use, but most importantly, because they aren’t invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing – offering patients the best chance of surviving their disease.

“This test is particularly exciting because it is multi-purpose, designed for use both before and after treatment, and using both the absolute amounts of cancer DNA in the bloodstream and also a readout of the specific mutations within that genetic material.

“We believe it can usher in a new era of precision medicine for prostate cancer.”

Each year, around 47,000 men in the UK are diagnosed with prostate cancer and more than 11,000 die from the disease.

Dr Matthew Hobbs, deputy director of research at the charity Prostate Cancer UK, which funded the research, said: “It’s clear that we need to move away from the current one-size-fits-all approach to much more targeted treatment methods.

“The results from this study and others like it are crucial as they give an important understanding of the factors that drive certain prostate cancers, or make them vulnerable to specific treatments.”

[“Source-ndtv”]

Cheap breath test may detect stomach, oesophageal cancers

Cheap breath test may detect stomach, oesophageal cancers (Thinkstock photos/Getty Images)Cheap breath test may detect stomach, oesophageal cancers (Thinkstock photos/Getty Images)
Scientists have developed a cheap and non-invasive test that can measure the levels of five chemicals in the breath to detect cancers of the oesophagus and stomach with 85 per cent accuracy.

Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide.

Both tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15 per cent.

Currently, the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy — an expensive, invasive method with some risk of complications.

“A breath test could be used as a non-invasive, first-line test to reduce the number of unnecessary endoscopies. In the longer term this could also mean earlier diagnosis and treatment and better survival,” said Sheraz Markar from Imperial College London.

Previous research suggested that there are differences in the levels of specific chemicals — butyric, pentanoic and hexanoic acids, butanal, and decanal — in patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer.

In the new study, presented at the European Cancer Congress 2017 in The Netherlands, the team collected breath samples from 335 people, who were measured for levels of the five chemicals to see which ones matched to the ‘chemical signature’ that indicated cancer.

The results showed that the test was 85 per cent accurate overall, meaning that the breath test was good at picking up those who had cancer (80 per cent sensitivity) and was also good at correctly identifying who did not have cancer (81 per cent specificity).

“This study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach and which do not,” Markar said.

source”cnbc”

Honor UK has launched a EMUI 5 beta test for the Honor 8

A few days ago, Huawei unveiled its new Mate 9 pair and really upped the stakes in the high-end smartphone market. Besides its undoubtedly impressive specs sheet, the Mate 9 also shines with the new and improved EMUI 5. It brings about numerous tweaks and changes, most of which stem directly from user feedback. And even though, Huawei specifically outlined the close integration between the OS and its new Kirin 960 chipset, it is good to hear that the OEM plans to bring the ROM to other handsets as well.

The Honor 8 will apparently be first in line as the UK branch of the company has already launched an EMUI 5 beta for the handset. You can find more info and download links at the source and there are a few steps you need to go through to actually participate in the beta. You need a FRD-L09 unit, based in the UK, with an active SIM card and a current OS build number of C432B131. The rest of the process is fairly straightforward. You have to download this package, unzip it and install the APK inside. Then use the new BETA app to get EMUI 5.

As for some of the highlight features, first there is finally an App drawer. Better yet, Huawei has made it opt-in, so if you prefer the old flat style, you can just toggle in and out of it live, no restarts required. The app drawer itself has a nifty search bar at the top, followed by a row of frequently used apps and then an alphabetical layout of all the rest. The letters on the right-hand side offer quick navigation trough said list.

Another neat trick in the new EMUI is App twin. It allows you to log into two accounts on supported apps. The Huawei Mate 9 offers an additional separate environment, accessed through putting an alternative finger on the scanner. Perhaps it will be part of the Honor 8 ROM as well.

Speaking of multiple apps, the task manager has been overhauled as well. It now has larger cards in a vertical layout. You can easily swipe away individual apps or clear all of them with one tap. There is also a convenient feature to lock them in place.

Of course, you get all the benefits from Android 7 Nougat, running under the hood as well. Plus, numerous other smaller tweaks and fixes all around the interface

source”cnbc”

XAT 2017: Check out test centres, paper pattern, other details here

All the candidates can check the complete examination schedule of Xavier Aptitude Test (XAT) 2017.

XAT 2017: Check out test centres, paper pattern, other details here

RELATED STORIES

  • ICAI IPC Intermediate, Final Exam 2016 begins: Check out complete test schedule here
  • FMS Delhi admissions 2017: Apply for MBA course
  • RRB NTPC results likely to be declared soon: Check at www.rrcb.gov.in
  • Punjab PSTET results to be announced soon: Check at www.tetpunjab.com
  • RPSC RAS/RST Combined Competitive (Mains) 2016 exam schedule released at rpsc.rajasthan.gov.in: Check now

The registration process for Xavier Aptitude Test (XAT) has already begun on the official website, http://xatonline.net.in/

The exam is scheduled to be conducted on January 8, 2017.

As per reports, it will be held by the Xavier School of Management (XLRI), Jamshedpur on behalf of the XAMI to select the most suitable students for management education.

For the first time, the institute will be holding the exam on the second Sunday instead of the first Sunday of the year. Apart from XLRI, the XAT scores are accepted by around 140 B-schools across India. Last year, XAT has undergone changes in terms of exam pattern.

Changes introduced last year:

  • The total number of questions in the main paper were brought down to 78
  • The time allotted was increased by 20 minutes
  • In XAT 2016, students had a choice of not attempting 13 questions
  • The number of questions in the GK section were reduced to 25.

Eligibility criteria

Educational qualification:

Those interested in applying should be holding a Bachelor’s degree in any discipline from a recognised university/institute. The duration of the programme should be a minimum of three years. Those in the final year of graduation are also eligible to apply.

Selection procedure:

The candidates will be shortlisted on the basis of the cut-offs set by each institute. The shortlisted candidates will then be asked to appear for a group discussion, written ability test and personal interview rounds.

Application fee:

All the candidates need to pay Rs 1600.

Exam pattern:

  • The test would be conducted from 10 am to 1.30 pm
  • XAT is a paper pencil based test divided into two papers
  • Paper 1 consists of 78 questions from quantitative ability and data interpretation, verbal ability and decision making and analytical reasoning
  • Paper 2 is a mix of objective as well as subjective questions from general knowledge and essay writing questions

Test centres:

Agartala Bhopal, Cuttack Guwahati Jamshedpur
Ahmedabad Bhubaneswar Dehradun Hyderabad  Kanpur
Allahabad Chandigarh Delhi Indore Kolkata
Amritsar Chennai Goa Jabalpur Lucknow
Bengaluru Cochin Greater Noida Jaipur Mangalore
Berhampur Coimbatore Gurgaon, Jammu Mumbai
Nagpur Nasik Noida Patna Pune
Raipur Ranchi Rourkela Sambalpur Surat
Tiruchirapalli Trivandrum Udaipur Vadodara Varanasi
Vijayawada Visakhapatnam

Also, XAT 2017 would be conducted across the following two international cities which include Dubai, Kathmandu.

How to apply:

All the candidates need to apply online.

Log on to the official website, http://xatonline.net.in/

Important dates:

  • Last date of application: November 30
  • Last date of late application: December 11
  • Download admit card: December 20
  • XAT 2017 exam: January 8, 2017
  • XAT 2017 Result: Last week of January, 2017.
  • source”cnbc”

Chikungunya Virus Has Tendency Not To Show In Common Serology Test: Ganga Ram Hospital

Chikungunya Virus Has Tendency Not To Show In Common Serology Test: Ganga Ram HospitalNEW DELHI:  The Sir Ganga Ram Hospital in New Delhi said it had recently found that the Chikungunya virus has a tendency not to show itself in the Chikungunya Igm serology test while it shows up during the RT-PCR test only, which the Hospital has been using it for the suspected samples.

Currently many of the hospitals in Delhi have been performing the Igm serology test, which is probably the reason why a lot of hospitals have not been able to confirm the presence of Chikungunya.

“This particular virus of Chikungunya has a tendency not to show itself in Chikungunya in the Igm serology test. Infact, in the last 10 days we applied Chikungunya Igm serology test in 385 samples and none of them were positive where as when we applied RT-PCR in 524 samples, a total of 293 samples came positive,” said Chand Wattal, Chairman of the Microbiology department at Sir Ganga Ram Hospital.

The RT-PCR test is being used by a very few hospitals currently in the national capital.

Ganga Ram Hospital has reported four deaths in last 24 hours due to various complications triggered due to Chikungunya. Delhi has witnessed a total of five deaths caused by the disease so far.

source”gsmarena”

Samsung Galaxy S7 active didn’t pass Consumer Reports’ water test, twice

Call it a fluke, or call it Samsung’s mistake. Consumer Reports is an American magazine and media outlet supported by its own subscribers to perform rigorous testing of all kinds of consumer products from cameras to cars.

The Galaxy S7 active (as well as the other S7 models) is rated for up to 5 feet deep of water for up to 30 minutes. Consumer reports simulated this test with the Galaxy S7 and S7 edge, but also did the same test for the Galaxy S7 active.

Consumer Reports uses a tank of water which is placed under 2.12 PSI (about 14.6 kPa) for 30 minutes to test Samsung’s claim. There were complications with the test performed on the Galaxy S7 active, as the phone was not able to survive the test without damage.

The water breached into the device and was apparent by the fogging which can be seen in the front and rear camera lenses, as well as the screen, which was not working normally either. There was also water coming out of the SIM tray upon its removal.

Naturally, Consumer Reports figured it could have been a defective device and decided to perform the same test again. The results for the second phone, surprisingly, were the same. Water also breached through the device’s exterior yet again.

Samsung was contacted and the phone maker is investigating the possible causes now. But it could be a number of possible things. Consumer Reports said the test were performed exactly the same for the S7 and S7 edge both of which succeeded with no issues. While it’s not known who is to blame in the situation, let’s speculate.

It had been several months since the Galaxy S7 and S7 edge were originally tested, perhaps the pressure gauge was not calibrated correctly prior to these new tests. Or perhaps the pressure was raised too suddenly for the phone to survive under those conditions.

Well, Consumer Reports is likely not at fault though. Perhaps the water breached through the barometer found on the Galaxy S7 active (Neither the S7 nor S7 edge have this feature which would explain why they didn’t fail the same test). It could be that the instrument which measures atmospheric pressure was not thoroughly tested for water resistance. Or it could even be a really small chance that Consumer Reports tested two defective units.

Because of this failure to pass the water test. Consumer Reports has said that “with this failure, we cannot recommend the Galaxy S7 active.” Ouch.
[“source -cncb”]

Google starts beta test of journeys, a new journey companion app

google trips preview

some leaked screenshots imply the app is greater approximately leveraging Google’s significant know-howof the planet from Maps so as to signify things to do for your travels. There are a whole lot ofrecommendations for things to move see and do even as you’re on the adventure at the side of the standard organizational help.

Your itinerary is pulled in from Gmail, with lodge remains, flight facts, automobile leases, and different info allaccrued collectively for easy get entry to.

if you’re a member of nearby courses and reached degree two or above, you could get an invite to try out the app on Android or iPhone. We’re working to score an invitation ourselves, so we’ll replace with any cool insights we select up.

The effect on you: Google’s said purpose is to prepare the world’s records, and currently that’s intended all your records. journey is a classic case where you can typically hit detail overload, and Google is tops at coming to the rescue with algorithms. How a whole lot you need the company to recognize approximatelyyou, of path, is a question you’ll need to grapple with.

New Ford EcoSport test mule spotted in China

New Ford EcoSport test mule spotted in China

The test mule images of the camouflaged Ford EcoSport has emerged from China. The upcoming vehicle will not just get cosmetic upgrades on the front and rear section, but it will also get a fresh interior upgrade.

The front fascia will sport a new hexagonal grille and restyled headlamps. The bumpers have been restyled, while the rear section gets tweaked tail lamps. The externally mounted rear wheel has also been taken out and finds place within the boot. The sides will look enhanced with redesigned alloys and turn indicator on ORVMs.

Speaking of the interiors, the new EcoSport will get a new display with customisation options, a new centre console and an updated SYNC infotainment system. The dual tone dashboard also gets new rectangular shaped air-conditioning vents which are located below the infotainment system. Like the one spotted in Brazil, the China spec-model will also feature a similar looking steering wheel and instrument console.

The China-spec EcoSport is expected to be powered by 1.0-litre EcoBoost petrol engine that will generate around 121bhp power, while the 1. 5-litre Ti-VCT petrol will generate about 108bhp of power. The engines will come mated to a five speed manual or a six speed Powershift DCT gearbox.

The new Ford EcoSport is expected to be up on sale in India sometime next year. The India-spec model will continue to be offered with the current engine options, while it might get some new design and feature upgrades.

Launched way back in 2013, the Ford EcoSport SUV has been a popular choice in the Indian market since then. The American automaker had recently introduced a more powerful diesel engine option in the Indian market and post the introduction of a new model, it is anticipated that the company will further witness a growth in sales.+

[“source -business-standard”]

New sight test detects early AMD

Researchers based at the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye Hospital and UCL Institute of Ophthalmology, received funding from Fight for Sight and the Special Trustees of Moorfields Eye Hospital NHS Foundation Trust which has resulted in the design of a new test that can spot the first stages of sight loss in age-related macular degeneration (AMD). The test could lead to earlier diagnosis for millions of people worldwide. Professor Roger Anderson led the research team.

AMD affects the macula – the central part of the light-sensitive layer of the eye (the retina) that we use for reading and recognising faces. In the UK, more than half a million over-50s have a form of AMD, and the figure is set to rise as the population ages.

Most sight loss from AMD happens in the later stages. But, until now, there has been no quick and reliable sight test that can detect the earliest changes in the retina in AMD.

Standard letter charts are not consistent or sensitive enough to give an early diagnosis accurately or to monitor AMD’s progress. This will become especially important as new treatments are developed that can prevent sight loss from AMD.

To address the problem, the team invented a new test chart, called the Moorfields Acuity Chart (MAC), that uses letters – known as ‘high-pass’ letters – built up from fine (high spatial frequency) black-and-white stripes. Their previous work showed that the high-pass letters are more equally readable than standard letters and that they seem to vanish altogether at the point when they are too small to be recognised.

In the current study the team compared the sensitivity of the new MAC test with the standard test used to measure clarity of visual perception in 80 AMD patients from Moorfields Eye Hospital and 38 people with normal vision. Participants were asked to read the letters from two versions of each type of chart, shown in random order. They were then given a visual acuity score based on the number of letters they could read before making 4 mistakes on one line.

Results showed that MAC charts produced more reliable results from one test to the next than using the standard charts for people with AMD. This was not the case for participants with normal vision. Importantly, the difference between MAC chart and standard chart scores was approximately 4.5 lines in people with AMD and better visual acuity compared to people without AMD who had similar visual acuity, where the difference was 1.5 lines.

Professor Roger Anderson supervised the Fight for Sight PhD student on the study. He said: “Through this important project, funded by Fight for Sight and supported by the NIHR Moorfields Biomedical Research Centre, we have designed a new vision test – the Moorfields Acuity Chart – that can more reliably detect the earliest vision loss associated with age-related macular degeneration so that we can enter patients on treatment regimes more quickly, and monitor them more reliably than ever before.”

Dr Dolores M Conroy, Director of Research at Fight for Sight, said: “Having a test that is sensitive to the changes specifically seen in early AMD, is easily understood by patients and that can be administered routinely in the clinic is a very important development that addresses a high priority for research as identified by the Sight Loss and Vision Priority Setting Partnership. We’re delighted to see that there has been worldwide interest in using the new charts.”

Professor Sir Peng Tee Khaw, Director of the NIHR Moorfields Biomedical Research Centre, said, “This marks a significant advancement in our ability to diagnose vision loss arising from the leading cause of sight loss in industrialised countries. This is exciting for us all as improved testing methods lead to better diagnosis and treatment development.”

The results are published in the British Journal of Ophthalmology. The chart will be produced commercially under licence by Peter Allen and Associates and the team is currently preparing to assess the MAC chart’s performance in a larger clinical trial.

[“source-gsmarena”]

Porsche’s next-gen Panamera V6 and Turbo spotted on test

Porsche

The second generation of the Porsche Panamera has been spied testing near Weissach, Germany. The test mules of both the standard V6 and the powerful Turbo were sighted taking rounds back to back.

If one looks closely beyond the pseudo headlamps and tail lamps, one can see the redesigned car, which still has the familiar styling of the current model. However, this successor still looks better than the car it will replace. The standard car (one in black) will get a revamped fascia with evolutionary headlights and LED turn indicators. Apart from the sculpted hood, the front fender vents and door mounted ORVMs are also tweaked. The aerodynamic car gets a sportier roofline, muscular rear fenders and a sporty dual exhaust system.

Porsche Panamera

In the Turbo (blue car), most of the components from the standard version are designed to look sportier. It comes paired with a high performance braking system and a four-tailpipe exhaust system. The former system uses brake calipers painted in yellow just to give it a sporty appeal. Both these variants essentially make up for a sleek and purposeful machine that has now become lighter and even more agile. All of this, thanks to the brand’s new MSB platform that incorporates the use of aluminium, lightweight composites and high-strength steel.

Porsche Panamera

There is no confirmation about the powertrain yet, but we can expect a variety of engine options. The entry-level V6 mill might power the standard models and there might be another mid-range V8 engine. Under the hood of the Turbo will be a 4.0-litre V8 powerplant. The automaker is also expected to offer a diesel-powered variant and another plug-in hybrid model.

Porsche will officially unveil the latest iteration of the Panamera at the Paris Motor Show in October this year. On the other hand, the Turbo variant will make its debut at the Geneva Motor show next year. Porsche sells all their models in India via the CBU route. Once this second-generation Panamera is introduced in the international markets, it will also come to our country following its global launch.

Porsche

The second generation of the Porsche Panamera has been spied testing near Weissach, Germany. The test mules of both the standard V6 and the powerful Turbo were sighted taking rounds back to back.

If one looks closely beyond the pseudo headlamps and tail lamps, one can see the redesigned car, which still has the familiar styling of the current model. However, this successor still looks better than the car it will replace. The standard car (one in black) will get a revamped fascia with evolutionary headlights and LED turn indicators. Apart from the sculpted hood, the front fender vents and door mounted ORVMs are also tweaked. The aerodynamic car gets a sportier roofline, muscular rear fenders and a sporty dual exhaust system.

Porsche Panamera

In the Turbo (blue car), most of the components from the standard version are designed to look sportier. It comes paired with a high performance braking system and a four-tailpipe exhaust system. The former system uses brake calipers painted in yellow just to give it a sporty appeal. Both these variants essentially make up for a sleek and purposeful machine that has now become lighter and even more agile. All of this, thanks to the brand’s new MSB platform that incorporates the use of aluminium, lightweight composites and high-strength steel.

Porsche Panamera

There is no confirmation about the powertrain yet, but we can expect a variety of engine options. The entry-level V6 mill might power the standard models and there might be another mid-range V8 engine. Under the hood of the Turbo will be a 4.0-litre V8 powerplant. The automaker is also expected to offer a diesel-powered variant and another plug-in hybrid model.

Porsche will officially unveil the latest iteration of the Panamera at the Paris Motor Show in October this year. On the other hand, the Turbo variant will make its debut at the Geneva Motor show next year. Porsche sells all their models in India via the CBU route. Once this second-generation Panamera is introduced in the international markets, it will also come to our country following its global launch.

[“source -pcworld”]